

**NATIONAL INSTITUTE FOR HEALTH AND CARE  
EXCELLENCE**

**NICE guidelines**

**Equality and health inequalities assessment (EHIA)  
template**

**Intrapartum care – management of postpartum  
haemorrhage**

The considerations and potential impact on equality and health inequalities have been considered throughout the guidance development, maintenance and update process according to the principles of the NICE equality policy and those outlined in [Developing NICE guidelines: the manual](#).

This EHIA relates to:

Update of table 12 in the NICE guideline on intrapartum care (NG235)

## Appendix B: equality and health inequalities assessment (EHIA)

### STAGE 1. Surveillance review

No surveillance review was carried out for this update.

### STAGE 2. Informing the scope

No scoping was carried out for this update.

### STAGE 3. Finalising the scope

No scoping was carried out for this update.

### STAGE 4. Development of guideline or topic area for update

*(to be completed by the developer before consultation on the draft guideline or update)*

Intrapartum care

Date of completion: 4 September 2024

Focus of guideline or update: Table 12 Choice of uterotonics for the treatment of postpartum haemorrhage because of uterine atony in the intrapartum care guideline (NG235)

4.1	From the evidence syntheses and the committee's considerations thereof, what were the main equality and health inequalities issues identified? Were any <b>further</b> potential issues identified (in addition to those identified during the scoping process) or any gaps in the evidence for any particular group?
	No scoping phase was carried out for this update.  Whilst we are aware of maternity being a key area in CORE20PLUS5, no equalities or health inequalities issues relevant to the specific update were identified by the committee.
4.2	How have the committee's considerations of equality and health inequalities issues identified in 2.2, 3.2 and 4.1 been reflected in the guideline or update and any draft recommendations?
	No equalities or health inequalities issues relevant to the update were identified by the committee.
4.3	Could any draft recommendations potentially increase inequalities?
	No.

4.4	How has the committee's considerations of equality and health inequalities issues identified in 2.2, 3.2 and 4.1 been reflected in the development of any research recommendations?
	No equality and health inequalities issues relevant to the update were identified by the committee.
4.5	Based on the equality and health inequalities issues identified in 2.2, 3.2 and 4.1, do you have representation from relevant stakeholder groups for the guideline or update consultation process, including groups who are known to be affected by these issues? If not, what plans are in place to ensure relevant stakeholders are represented and included?
	No equalities or health inequalities issues relevant to the update were identified by the committee. Various organisations that can provide comments in relation to equalities and health inequalities issues relevant to the update have been invited to register to become stakeholders.
4.6	What questions will you ask at the stakeholder consultation about the impact of the guideline or update on equality and health inequalities?
	None.

**Completed by developer:** Maija Kallioinen

**Date:** 4 September 2024

**Approved by committee chair:** Sarah Fishburn

**Date:** 15/9/24

**Approved by NICE quality assurance lead:** Sara Buckner

**Date:** 18 September 2024

## STAGE 5. Revisions and final guideline or update

*(to be completed by the developer before guidance executive considers the final guideline or update)*

Intrapartum care

**Date of completion:** 11<sup>th</sup> November 2024

Focus of guideline or update: Table 12 Choice of uterotonics for the treatment of postpartum haemorrhage because of uterine atony in the intrapartum care guideline (NG235)

5.1 How inclusive was the consultation process on the draft guideline in terms of response from groups (identified in box 2.2, 3.2 and 4.1) who may experience inequalities related to the topic?

*A total of 338 stakeholders are on the list for this guideline, of which 10 responded to the consultation. These stakeholders represent national healthcare organisations, charities, groups representing those with lived experience, government departments, healthcare service providers, professional organisations and medical royal colleges.*

Quality of responses were generally very good. No further equality and health inequalities issues were raised.

5.2 Have any **further** equality and health inequalities issues beyond those identified at scoping and during development been raised during the consultation on the draft guideline or update, and, if so, how has the committee considered and addressed them?

No further equalities and health inequalities issues beyond those identified during development were raised at consultation:

5.3 If any recommendations have changed after consultation, how could these changes impact on equality and health inequalities issues?

A statement has been added alerting people to a National Patient Safety Alert on risk of oxytocin overdose during labour and childbirth. This should have no effect on the access to services, but should ensure that all groups of people have access to information needed to provide safe and effective care.

5.4 Following the consultation on the draft guideline and response to questions 4.1 and 5.2, have there been any further committee considerations of equality and health inequalities issues across the four dimensions that have been reflected in the final guideline?

Nothing in addition to points discussed in section 4.1

5.5 Please provide a summary of the key equality and health inequalities issues that should be highlighted in the guidance executive report before sign-off of the final guideline or update

This was a very small update to change the medicines recommended for use in treatment of post-partum haemorrhage. Whilst we are aware of maternity being a key area in CORE20PLUS5, no equalities or health inequalities issues relevant to the specific update were identified by the committee.

**Completed by developer:** Sara Buckner

**Date:** 11<sup>th</sup> November 2024

**Approved by committee chair:** Sarah Fishburn

**Date:** 12/11/24

**Approved by NICE quality assurance lead:** Kate Kelley

**Date:** 17/11/24

**STAGE 6. After guidance executive amendments – only if applicable**

***(to be completed by appropriate NICE staff member after guidance executive. This stage should be skipped if GE does not apply)***

Intrapartum care

**Date of completion:** 28<sup>th</sup> November 2024

Focus of guideline or update: Table 12 Choice of uterotonics for the treatment of postpartum haemorrhage because of uterine atony in the intrapartum care guideline (NG235)

6.1 Outline any amendments related to equality and health inequalities issues suggested by guidance executive and what the outcome was.
No further equalities and health inequalities issues beyond those identified during development were raised at GE:

**Completed by developer:** Sara Buckner

**Date:** 28<sup>th</sup> November 2024

**Approved by committee chair:** Sarah Fishburn

**Date:** 28/11/24

**Approved by NICE quality assurance lead:** Kate Kelley

**Date:** 02/12/24